EuroClonality logo

Diagnostic innovations developed by EuroClonality

Two central aims of EuroClonality are innovation and standardization. For almost 30 years, researchers from the laboratories connected to EuroClonality have been collaborating to develop new diagnostic tests (assays) for lymphoid malignancies, and to standardize their use. These innovations are used by laboratories worldwide to obtain more accurate information on diagnosis and prognosis of (potential) leukemia and lymphoma patients, in a shorter timeline. Furthermore, standardization facilitates optimal use of the tests and comparison of results between laboratories. This means that patients with acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, multiple myeloma and other diseases can be treated faster and more efficiently, resulting in longer life expectancy and better quality of life.

The most important and impactful innovations of EuroClonality are:

Multiplex PCR assays for analysis of IG/TR rearrangements: Gold standard for clonality assessment
One-tube assay for analysis of TRG rearrangements
Capture-based NGS integrated lymphoma panel
Amplicon-based NGS IG/TR assays for clonality assessment and MRD marker identification
Quality control samples
IGHV leader primer assay for mutational status assessment and MRD measurement
Bioinformatics pipelines for NGS IG/TR data analysis